Recent advances in the construction of antibody-drug conjugates

Nature Chemistry

Volumn 8, Issue 2, 2016, Pages 114-119

  Chudasama, Vijay ^a   Maruani, Antoine ^a   Caddick, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; DRUG; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; CHEMISTRY; DRUG DESIGN; HUMAN;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; PHARMACEUTICAL PREPARATIONS;

EID: 84955494300     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.2415     Document Type: Review

References (50)

1. Ehrlich, P. Address in pathology, ON CHEMIOTHERAPY: Delivered before the seventeenth international congress of medicine. Brit. Med. J. 2, 353-359 (1913).
2. Mathé, G., Loc, T. B. & Bernard, J. Effet sur la leucémie 1210 de la souris d'une combinaison par diazotation d'A-méthoptérine et de γ-globulines de hamsters porteurs de cette leucémie par hétérogreffe. C.R. Hebd. Séances Acad. Sci. 246, 1626-1628 (1958).
3. Ghose, T. & Nigam, S. P. Antibody as carrier of chlorambucil. Cancer 29, 1398-1400 (1972).
4. Rowland, G. F., O'Neill, G. J. & Davies, D. A. L. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 255, 487-488 (1975).
5. Ford, C. H. J. et al. Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Brit. J. Cancer 47, 35-42 (1983).
6. Trail, P. A. et al. Cure of xenografted human carcinomas by Br96-doxorubicin immunoconjugates. Science 261, 212-215 (1993).
7. Pietersz, G. A. & Krauer, K. Antibody-targeted drugs for the therapy of cancer. J. Drug Target. 2, 183-215 (1994).
8. Linenberger, M. L. et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98, 988-994 (2001).
9. Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812-1821 (2010).
10. Senter, P. D. & Sievers, E. L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnol. 30, 631-637 (2012).
11. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783-1791 (2012).
12. Lo Russo, P. M., Weiss, D., Guardino, E., Girish, S. & Sliwkowski, M. X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 17, 6437-6447 (2011).
13. Mullard, A. Maturing antibody-drug conjugate pipeline hits 30. Nature Rev. Drug Discov. 12, 329-332 (2013).
14. Hamblett, K. J. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004).
15. Stan, A. C., Radu, D. L., Casares, S., Bona, C. A. & Brumeanu, T. D. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res. 59, 115-121 (1999).
16. Strop, P. et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20, 161-167 (2013).
17. Lyons, A. et al. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng. 3, 703-708 (1990).
18. Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnol. 26, 925-932 (2008).
19. Sunbul, M. & Yin, J. Site specific protein labeling by enzymatic posttranslational modification. Org. Biomol. Chem. 7, 3361-3371 (2009).
20. Young, T. S., Ahmad, I., Yin, J. A. & Schultz, P. G. An enhanced system for unnatural amino acid mutagenesis in E. coli. J. Mol. Biol. 395, 361-374 (2010).
21. Rabuka, D., Rush, J. S., de Hart, G. W., Wu, P. & Bertozzi, C. R. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nature Protoc. 7, 1052-1067 (2012).
22. Axup, J. Y. et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl Acad. Sci. USA 109, 16101-16106 (2012).
23. Junutula, J. R. et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332, 41-52 (2008).
24. Woo, H. J., Lotz, M. M., Jung, J. U. & Mercurio, A. M. Carbohydrate-binding protein 35 (Mac-2), a laminin-binding lectin, forms functional dimers using cysteine 186. J. Biol. Chem. 266, 18419-18422 (1991).
25. Wootton, S. K. & Yoo, D. Homo-oligomerization of the porcine reproductive and respiratory syndrome virus nucleocapsid protein and the role of disulfide linkages. J. Virol. 77, 4546-4557 (2003).
26. Greenberg, C. S., Birckbichler, P. J. & Rice, R. H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 5, 3071-3077 (1991).
27. Kanaji, T. et al. Primary structure of microbial transglutaminase from Streptoverticillium sp. strain s-8112. J. Biol. Chem. 268, 11565-11572 (1993).
28. Kashiwagi, T. et al. Crystal structure of microbial transglutaminase from Streptoverticillium mobaraense. J. Biol. Chem. 277, 44252-44260 (2002).
29. Jeger, S. et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. 49, 9995-9997 (2010).
30. Wu, P. et al. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc. Natl Acad. Sci. USA 106, 3000-3005 (2009).
31. Drake, P. M. et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjugate Chem. 25, 1331-1341 (2014).
32. Zimmerman, E. S. et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjugate Chem. 25, 351-361 (2014).
33. Sapra, P. et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol. Cancer Ther. 12, 38-47 (2013).
34. Tian, F. et al. A general approach to site-specific antibody drug conjugates. Proc. Natl Acad. Sci. USA 111, 1766-1771 (2014).
35. Sun, M. M. et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chem. 16, 1282-1290 (2005).
36. Doronina, S. O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnol. 21, 778-784 (2003).
37. Beckley, N. S., Lazzareschi, K. P., Chih, H.-W., Sharma, V. K. & Flores, H. L. Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjugate Chem. 24, 1674-1683 (2013).
38. Shen, B. Q. et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nature Biotechnol. 30, 184-189 (2012).
39. Lyon, R. P. et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nature Biotechnol. 32, 1059-1062 (2014).
40. Badescu, G. et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjugate Chem. 25, 1124-1136 (2014).
41. Nunes, J. P. M. et al. Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC). Chem. Commun. 51, 10624-10627 (2015).
42. Maruani, A. et al. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nature Commun. 6, 7645 (2015).
43. Maruani, A. et al. Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic. Chem. Commun. 51, 15304-15307 (2015).
44. Lee, M. T. W., Maruani, A., Baker, J., Caddick, S. & Chudasama, V. Next-generation disulfide stapling: Reduction and functional re-bridging all in one. Chem. Sci. 7, 799-802 (2016).
45. Hinman, L. M. et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 53, 3336-3342 (1993).
46. Hamann, P. R. et al. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjugate Chem. 16, 346-353 (2005).
47. Wang, W. et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol. Immunol. 48, 860-866 (2011).
48. Zhou, Q. et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjugate Chem. 25, 510-520 (2014).
49. Li, X., Fang, T. & Boons, G. J. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew. Chem. Int. Ed. 53, 7179-7182 (2014).
50. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21, 11-16 (2005).